Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2252W HIGH $5.48
Volume
30.95 K
Value Traded
110.94 K
Short % Float
0.7%
-11.89%Week
-59.74%1 Month
-57.86%3 Month
-64.9%6 Month
-78.13%5 Year
-91.57%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
125.42 M
EPS (TTM)
-0.67
P/E Ratio
-
Ent. Value
180.00 M
Total Shares
100.34 M
Float Shares
69.48 M
Insiders
3.93%
Institutions
13.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CLLS Catalyst Timeline
Dated clinical, regulatory and corporate events for Cellectis S.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cellectis S.A.
837Total events
20Upcoming
110Tier-1 (high impact)
2014 to 2028Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Cellectis to host conference call and webcast to provide a business update
▼Program DiscontinuationUCART22FiledCorporate
Cellectis to exit development of lasme-cel
B-ALLsource ↗
▼Restructuring LayoffsCorporate
Operational realignment and restructuring to focus on in vivo gene editing
▲Preclinical PoCHEAL-101Preclinical
HEAL-101 preclinical proof-of-concept in humanized murine models
severe hypertriglyceridemiasource ↗
▲Preclinical PoCHEAL-201Preclinical
HEAL-201 preclinical proof-of-concept in humanized murine model
severe hypercholesterolemiasource ↗
▼Program DiscontinuationUCART22FiledCorporate
Cellectis will exit development of lasme-cel
B-ALLsource ↗
▼Restructuring LayoffsCorporate
Cellectis realigns organization and resources to focus on in vivo gene editing pipeline
▲Other Regulator MilestoneUCART22FiledEx-US Regulatory
Enrollments authorized in France, Italy, and Spain for Phase 2 BALLI-01
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲RMATcema-celDesignation
FDA granted RMAT designation to cema-cel
large B-cell lymphoma (LBCL) with minimal residual disease (MRD)source ↗
▲Fast Track Designationcema-celDesignation
FDA granted Fast Track designation to cema-cel
large B-cell lymphoma (LBCL) with minimal residual disease (MRD)source ↗
▲Full ResultsALLO-316Clinical Data
Publication of complete Phase 1 data from TRAVERSE study of ALLO-316
advanced or metastatic renal cell carcinoma (RCC)source ↗
◆Quarterly UpdateCorporate
Combined General Meeting of Shareholders to approve financial statements and other resolutions
◆Oral PresentationUCART22FiledPresentation
Safety and efficacy of UCART22 in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): results of the Phase 1 BALLI-01 trial
B-cell acute lymphoblastic leukemia (B-ALL)source ↗
◆Poster PresentationUCART20x22Presentation
Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study
relapsed or refractory B-cell non-Hodgkin lymphomasource ↗
◆Oral PresentationUCART22FiledPresentation
Presentations available on Cellectis website
relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
◆Oral PresentationUCART20x22Presentation
Presentations available on Cellectis website
relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)source ↗
▲RMATUCART22FiledDesignation
FDA granted RMAT designation for lasme-cel
leucémie lymphoblastique aigüe à cellules B (LLA-B) en rechute ou réfractairesource ↗
▲Enrollment MilestoneUCART22FiledTrial
Pivotal Phase 2 of BALLI-01 open for enrollment
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲RMATUCART22FiledDesignation
FDA granted RMAT designation for lasme-cel
relapsed or refractory CD22 positive B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲Oral PresentationUCART22FiledPresentation
Full Phase 1 data from BALLI-01 presented at EHA 2026
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲Other Regulator MilestoneUCART22FiledEx-US Regulatory
MHRA approved initiation of Phase 2 BALLI-01 in the UK
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
▲Poster PresentationUCART20x22Presentation
Translational data from NATHALI-01 presented at EHA 2026
relapsed or refractory non-Hodgkin lymphoma (r/r NHL)source ↗
▲MHRA MilestoneUCART22FiledEx-US Regulatory
MHRA approved initiation of Phase 2 BALLI-01 in UK
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
◆Poster PresentationPresentation
Presentation of TALE-based epigenetic modulators at ASGCT annual meeting
◆AbstractUCART22FiledPresentation
Abstract for BALLI-01 Phase 1 data published on EHA website
relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
◆AbstractUCART20x22Presentation
Abstract for NATHALI-01 preliminary analysis published on EHA website
relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)source ↗
◆Interim Analysiscema-celTrial
Interim pivotal data reported from ALPHA3 trial of cema-cel (n=24)
large B-cell lymphoma (LBCL)source ↗
▲Interim Analysiscema-celTrial
Interim futility analysis of ALPHA3 trial for cema-cel in DLBCL shows MRD negativity rate of 58.3% vs 16.7% in observation arm
diffuse large B-cell lymphoma (DLBCL)source ↗
◆Interim Analysiscema-celTrial
Interim futility analysis evaluating MRD clearance and early safety results planned for April 2026
first-line consolidation in large B-cell lymphoma (LBCL)source ↗
◆Oral PresentationPresentation
Conference call to discuss financial results and business update
◆Trial InitiationUCART20x22Trial
Start recruitment of IL-2 support cohort in NATHALI-01
relapsed/refractory non-Hodgkin lymphomasource ↗
◆Enrollment MilestoneUCART20x22Trial
Début du recrutement de patients dans la cohorte IL-2
lymphome non Hodgkinien (LNH) en rechute ou réfractairesource ↗
◆Interim Analysiscema-celTrial
Interim EFS analysis for cema-cel ALPHA3 trial
large B-cell lymphoma (LBCL)source ↗
◆License DisputeIP / Competition
Arbitral Tribunal issues decision in dispute with Servier regarding License Agreement
◆IP Litigation RulingIP / Competition
Arbitration tribunal ruling in dispute with Servier regarding UCART19 V1 license
▲Oral PresentationUCART20x22Presentation
ASH 2025 presentation of updated data for eti-cel in r/r NHL
relapsed/refractory non-Hodgkin lymphomasource ↗
▲Poster PresentationUCART20x22Presentation
Présentation de nouvelles données encourageantes de l'essai NATHALI-01 à l'ASH 2025
lymphome non Hodgkinien (LNH) en rechute ou réfractairesource ↗
◆Poster PresentationUCART22FiledPresentation
Poster presentation on alemtuzumab exposure and response with lasme-cel at ASH 2025
relapsed/refractory acute lymphoblastic leukemiasource ↗
◆Poster PresentationUCART22FiledPresentation
Poster presentation on correlation between alemtuzumab exposure and response in BALLI-01 trial at ASH 2025
relapsed or refractory acute lymphoblastic leukemiasource ↗
◆Poster PresentationUCART20x22Presentation
Poster presentation of development update on eti-cel at ASH 2025
relapsed/refractory non-Hodgkin lymphomasource ↗
◆Poster PresentationUCART20x22Presentation
Poster presentation on updated development of éti-cel including IL-2 low-dose cohorts at ASH 2025
relapsed or refractory B-cell non-Hodgkin lymphomasource ↗
Past FDA Catalysts and PDUFA Decisions
How CLLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-13 | lasme-cel | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$6M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Cellectis S.A. faces pipeline headwinds (33/100), with $176M risk-adjusted pipeline value, led by UCART22 in B-cell Acute Lymphoblastic Leukemia (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UCART22 Monoclonal antibodyNCT04150497 | B-cell Acute Lymphoblastic Leukemia | Phase 1 | RECRUITING | 52 | Jun 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLLS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lasmé-cel RMAT | B-cell acute lymphoblastic leukemia | Phase 1 | 2026-06-11 | overall response rate: 100% (7/7); complete remission rate: 57% (4/7); minimal residual disease negative: 75%Read More | Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.6 % (-25 %) | 1.10 M | 87.10 K | 1.24% ( 1.07 K) |
CLLS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLLS ranks across every disease it competes in
Competitive Position is a premium feature
See how CLLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLLS News
CLLS▼ -41%on this news· ran to -53% by day 3
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
Cellectis has announced a strategic transformation to focus on in vivo gene editing, advancing two lead programs, HEAL-101 and HEAL-201, targeting severe dyslipidemias. The company plans to initiate Phase 1 trials in China with preliminary data expected in 2027 and 2028. This shift comes as Cellectis exits the development of lasme-cel and eti-cel due to changing market dynamics.
Read more →CLLS▼ -41%on this news· ran to -53% by day 3shared move
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
Cellectis will host a conference call and webcast on September 14, 2026, to provide a business update. The event will feature sessions in both English and French, allowing broader accessibility. Cellectis is known for its innovative gene editing platform aimed at developing cell and gene therapies, particularly in oncology.
Read more →CLLSMonthly information on share capital and company voting rights
Cellectis has released its monthly information regarding share capital and voting rights, as of September 3, 2026. The announcement includes details pertinent to its listing on Euronext Growth and provides contact information for media and investor relations. This update is part of the company's ongoing communication with stakeholders.
Read more →CLLSCellectis Announces Participation in Upcoming Investor Conferences
Cellectis has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Baird 2026 Global Healthcare Conference. The company aims to engage with investors and provide insights into its pioneering gene editing platform for cell and gene therapies. Cellectis' management will be available for meetings throughout these events.
Read more →CLLS▲ +5.4%on this news
Cellectis Reports Financial Results for the Second Quarter 2026
Cellectis reported its financial results for Q2 2026, highlighting significant advancements in its clinical trials. The company received FDA RMAT designation for lasme-cel, which shows promising efficacy in treating relapsed or refractory B-cell malignancies. The first interim analysis for the pivotal Phase 2 trial is expected in Q4 2026. Cellectis maintains a strong cash position, ensuring operational funding through Q4 2027.
Read more →CLLSCellectis to Report Second Quarter Financial Results on August 6, 2026
Cellectis has announced it will report its financial results for the second quarter of 2026 on August 6, 2026. The report will be available on the company's website after the US market closes. Notably, Cellectis will not hold a conference call to discuss these results, but its investor relations team is available for inquiries.
Read more →CLLSCellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis conducted its shareholders meeting on June 25, 2026, in Paris, where 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted, while resolution 30 was rejected. The meeting reflects strong shareholder engagement and support for the company's initiatives in gene-editing and cell therapies.
Read more →CLLSCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Cellectis presented final Phase 1 results for lasme-cel and preliminary data for eti-cel at the EHA 2026 Congress. The BALLI-01 trial showed a 100% overall response rate in the target population for lasme-cel, while the NATHALI-01 study indicated promising results for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma. Both therapies demonstrated manageable safety profiles and are open for further patient recruitment.
Read more →CLLSCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Cellectis announced that the FDA has granted RMAT designation to its allogeneic CAR-T therapy, lasme-cel, for treating relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This designation highlights the therapy's potential to meet significant medical needs. Phase 1 data showed promising results, and the pivotal Phase 2 trial is now open for enrollment.
Read more →CLLSCELLECTIS A corporation (“SA”) with a share capital of 5,029,549.70 euros Registered office : 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “ Company ”)
Cellectis SA has announced a combined general meeting scheduled for June 25, 2026, to discuss several key items, including the approval of the annual financial statements for 2025. During this period, the company experienced a substantial loss of 61,849,605 euros. The meeting will also address various authorizations for share capital increases and the renewal of several board members. Investors may need to consider the implications of these financial challenges and potential dilution of shares caused by ongoing capital management proposals.
Read more →CLLSCellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Cellectis has announced its annual general meeting scheduled for June 25, 2026, in Paris. The meeting will take place at the Biopark auditorium at 2:30 p.m. CET. This event reflects the company's commitment to transparency and governance as it continues to develop innovative gene-editing therapies.
Read more →CLLSCellectis Reports Financial Results for the First Quarter 2026
Cellectis reported its financial results for Q1 2026, highlighting a cash position of $188 million. The company is advancing its pivotal Phase 2 trial for lasme-cel in relapsed or refractory B-ALL and expects to present full Phase 1 data for eti-cel in relapsed or refractory NHL in Q4 2026. Despite a decrease in revenues and an increase in R&D expenses, interim data from Allogene's cema-cel trial offers validation for Cellectis' approach to CAR-T therapies.
Read more →CLLSCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Cellectis announced it will present clinical data on lasme-cel and eti-cel at the EHA 2026 Annual Congress. The BALLI-01 trial data for lasme-cel, a CAR-T therapy for relapsed B-ALL, shows promising safety and efficacy, while the NATHALI-01 trial for eti-cel in B-NHL will provide insights into treatment optimization. Both trials are pivotal for future developments.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three month period ended
Cellectis S.A. has released its unaudited condensed consolidated financial statements for the quarter ended March 31, 2026. The report indicates a decrease in total assets and a substantial net loss compared to the previous quarter. Total revenues and other income have also significantly dropped while operating expenses have increased. Furthermore, the report includes forward-looking statements which carry inherent risks and uncertainties that could affect the company's future performance.
Read more →CLLS▼ -6.3%on this news
Cellectis to Report First Quarter Financial Results on May 11, 2026
Cellectis has announced it will report its financial results for the first quarter of 2026 on May 11, 2026, after the US market closes. The company will not hold a conference call to discuss these results, but its investor relations team is available for inquiries. Cellectis specializes in gene-editing technologies for cell and gene therapies.
Read more →CLLSCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Cellectis showcased its TALE-based epigenetic editing platform at the ASGCT annual meeting. This innovative approach allows for gene regulation without altering DNA, presenting a safer alternative to traditional methods. The research demonstrated over 90% reduction in gene activity for specific targets, highlighting the effectiveness of their high-throughput screening system. The findings contribute to the expanding gene editing toolbox for therapeutic applications.
Read more →CLLSCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Cellectis highlights positive interim data from Allogene's pivotal ALPHA3 trial of cema-cel for large B-cell lymphoma. The trial showed a significant difference in minimal residual disease (MRD) negativity between the treatment and observation arms. The treatment was well-tolerated with no serious adverse events reported. Cellectis anticipates further developments in the trial, with potential for a Biologics License Application submission if results remain positive.
Read more →CLLSCellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Cellectis reported its financial results for 2025, highlighting significant progress in its clinical trials, particularly with lasme-cel, which achieved a 100% response rate in its Phase 2 study. The company anticipates submitting a Biologics License Application in 2028, marking a pivotal moment for its CAR-T therapies. However, it also faced increased operational costs and a notable financial loss compared to the previous year.
Read more →About Cellectis S.A.
BIOPHARMAWATCH ELITE PLUS
Trade the next CLLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime